SCHEMBL3340439

SCHEMBL3340439

COc1cc(Cl)c(-c2nnc(-c3cn4cc(C(F)(F)F)cc(Cl)c4n3)s2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
NFKB1 P19838 4/20 0.53
RAB9A P51151 4/20 0.53
NFKB2 Q00653 4/20 0.53
RELA Q04206 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
PKM P14618 1/20 0.43
SUV39H2 Q9H5I1 13/20 0.35
F2RL3 Q96RI0 1/20 0.32
AGPAT2 O15120 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3343175 0.92 SMN1; SMN2 (0.52) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3341189 0.86 NPC1 (0.43) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL13330599 0.85 NPC1 (0.44) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3343448 0.85 NPC1 (0.43) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340935 0.84 SMN1; SMN2 (0.50) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL18360200 0.84 SMN1; SMN2 (0.54) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3341811 0.83 NPC1 (0.41) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340056 0.82 NPC1 (0.42) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340395 0.82 S1PR1 (0.48) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3341131 0.82 S1PR1 (0.48) NPC1NFKB1RAB9ANFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 NPC1 241/4885NFKB1 3452/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.